Clinical trial
Bacillus Calmette-Guerin (BCG) Vaccine and Morbidity From Malaria
NCT00131794 · London School of Hygiene and Tropical Medicine, Other · Completed
Key facts
| NCT number | NCT00131794 |
|---|---|
| Title | Bacillus Calmette-Guerin (BCG) Vaccine and Morbidity From Malaria |
| Official title | The Effect of BCG Vaccine on Morbidity From Malaria |
| Lead sponsor | London School of Hygiene and Tropical Medicine, Other |
| Collaborators | Bandim Health Project Hospital Nacional Simao Mendes, Bissau Statens Serum Institut |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Malaria |
| Intervention type | Biological |
| Interventions | BCG |
| Enrollment | 1,200 |
| Start date | Jan 1, 2003 |
| Completion | Dec 1, 2003 |
| First posted | Aug 19, 2005 |
| Last update posted | Sep 2, 2016 |
| Countries | Guinea-Bissau |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: